VXA G1.1 NN
Alternative Names: GI.1 oral vaccine tablet - Vaxart; GI.1 vaccine - Vaxart; H1N1 (high dose) Oral Vaccine Tablet; H1N1 (low dose) Oral Vaccine Tablet; Monovalent GI.1 tableted vaccine - Vaxart; Norovirus GI.1 vaccine; VXA-G1-1-NN; VXA-G1.1-NNLatest Information Update: 26 May 2025
At a glance
- Originator Vaxart
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Norovirus infections
Most Recent Events
- 14 May 2025 Efficacy, adverse events and immunogenicity data from a phase II trial in Norovirus infections (Prevention) released by Vaxart
- 06 May 2025 VXA G1.1 NN is still in phase I development in Norovirus-infections (In the elderly, Prevention, In adults, In volunteers) in USA (PO, Tablet)
- 05 Mar 2025 Immunogenicity and adverse events data from phase I clinical trials in Norovirus infections released by Vaxart